** Drug developer KalVista Pharmaceuticals KALV.O decline about 7.4% to $12 premarket
** FDA extends review of KALV's experimental drug, sebetralstat, citing heavy workload and limited resources
** Health Secretary Robert F. Kennedy Jr. directed the FDA to fire 3,500 employees as part of a massive restructuring of U.S. health agencies in March
** TD Cowen says that the delay does not appears to do with the drug's safety or efficacy
** "Although disappointing, we expect little impact on the launch," says brokerage, adding that they expect significant demand from patients who suffer from a type of swelling disorder called hereditary angioedema
** Co says FDA plans to deliver a decision within four weeks
** KALV up 53% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.